



MOREPEN



Date: 31/03/2025

To,

National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Symbol: MOREPENLAB

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Scrip Code: 500288

Subject: Acquisition of common stock by Morepen Bio, Inc., a Wholly Owned Subsidiary of the Company

Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Dear Sir/ Madam,

This is to inform you that the Company had received an intimation today *i.e.*, March 31, 2025, at 6:05 pm (IST) from Morepen Bio, Inc., a Wholly Owned Subsidiary based in the U.S.A., w.r.t., acquisition of 135,000 of common stock in ICB International, Inc., a California-based corporation, for a total amount of USD 675,000, effective as of March 1, 2025.

Pursuant to Regulation 30(4)(i)(c), the acquisition cost mentioned above qualifies as a material event for the Company.

The details, as required under the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is given under as **Annexure**.

Thanking you,

Yours faithfully,

For Morepen Laboratories Limited

Vipul Kumar Srivastava
Company Secretary
F-12148

Encl.: a/a.

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com



Annexure

Disclosure under Regulations 30 of the SEBI LODR Regulations, read with circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024.

Sr.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.	ICB International, Inc., a California Corporation.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Not applicable
c)	Industry to which the entity being acquired belongs	Biotechnology
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The acquisition was made into normal course of business.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
f)	Indicative time period for completion of the acquisition	Not applicable
g)	Consideration - whether cash consideration or share swap or any other form and details of the same.	Cash, in multiple trances.
h)	Cost of acquisition and/or the price at which the shares are acquired	135,000 no. of common stock of ICB International, Inc., a California Corporation, at an aggregate sum of USD 675,000.
i)	Percentage of shareholding / control acquired and / or number of shares acquired	135,000 no. of common stock
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	The target company is engaged into the business of biotechnology.

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com